On Sept. 8, 2025, Femasys announced it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) for its FemBloc Permanent Birth Control. This approval confirms that FemBloc meets the country’s standards for safety, quality, and effectiveness, and represents an important milestone in Femasys’ global expansion strategy to make this revolutionary non-surgical permanent birth control option available to women worldwide.

New Zealand represents a strategically important healthcare market in the Asia-Pacific region, with a strong focus on advancing women’s health and equitable access to innovative treatments. Under its publicly funded healthcare system, technologies that improve outcomes and reduce costs have a clear pathway to adoption. Securing MEDSAFE approval not only validates FemBloc’s safety and effectiveness but also enables Femasys to provide women in New Zealand with access to a groundbreaking, non-surgical permanent birth control option.

FemBloc is a first-of-its-kind, non-surgical solution for permanent birth control, addressing a significant unmet need in women’s reproductive health. It uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue for permanent occlusion. In contrast to surgical sterilization, FemBloc eliminates the risks of anesthesia, infection, and recovery downtime, making it safer, more accessible, and significantly more cost-effective. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential.